# United Therapeutics Corporation > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/United Therapeutics Corporation). ## Overview United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies. Its commercial portfolio includes inhaled, oral, and injectable medicines, plus delivery devices and related services, sold primarily in the United States with additional international sales for selected products. ## Products & services • Tyvaso DPI inhalation powder for PAH and PH-ILD • Nebulized Tyvaso inhalation solution and delivery system • Remodulin injection and Remunity pump system • Orenitram extended-release tablets for PAH • Unituxin injection for high-risk neuroblastoma • Adcirca tablets for PAH • Ex vivo lung perfusion services and organ technologies - **Treprostinil-based PAH therapies** (90%) — Tyvaso DPI, Nebulized Tyvaso, Remodulin, and Orenitram for pulmonary arterial hypertension and related lung disease. - **Oncology** (7%) — Unituxin for treatment of high-risk neuroblastoma. - **Legacy PAH therapy** (1%) — Adcirca tablets sold in the United States for PAH. - **Other and services** (2%) — Commercial ex vivo lung perfusion services and other revenue items. - Tyvaso DPI inhalation powder for PAH and PH-ILD - Nebulized Tyvaso inhalation solution and delivery system - Remodulin injection and Remunity pump system - Orenitram extended-release tablets for PAH - Unituxin injection for high-risk neuroblastoma - Adcirca tablets for PAH - Ex vivo lung perfusion services and organ technologies ## Customers The company sells primarily to specialty pharmaceutical distributors and wholesale channels, which then supply patients through specialty pharmacy networks and healthcare providers. Its end customers are patients with PAH, PH-ILD, and high-risk neuroblastoma, with prescribing driven by specialist physicians in pulmonary hypertension and pediatric oncology. Outside the U.S., the company relies on international distributors for selected products. Demand is shaped by diagnosis rates, treatment adoption, reimbursement, and distributor inventory patterns. - **U.S. specialty pharmacy distributors** (primary) — Buy treprostinil-based therapies and Orenitram for dispensing to patients; inventory levels and ordering patterns affect shipments. - **International distributors** (secondary) — Buy Nebulized Tyvaso, Remodulin, and Unituxin for resale in approved markets outside the U.S. - **Hospitals and oncology treatment centers** (secondary) — Use Unituxin in high-risk neuroblastoma treatment protocols through oncology distribution channels. - **Specialist prescribers** (primary) — Pulmonary hypertension and lung disease specialists drive adoption of Tyvaso, Remodulin, and Orenitram. - **Patients with rare diseases** (primary) — End users of the therapies; demand depends on diagnosis, disease progression, and reimbursement access. - Specialty distributors such as Accredo and CVS Specialty - Cencora Global Procurement for U.S. Unituxin distribution - International distributors in Asia, the Middle East, Latin America, and Europe - Pulmonary hypertension specialists treating PAH and PH-ILD patients - Pediatric oncologists prescribing Unituxin for high-risk neuroblastoma ## Geography United Therapeutics is headquartered in the United States and generates most revenue there, with commercial distribution centered on U.S. specialty pharmacy and hospital channels. It also sells selected products internationally, including Nebulized Tyvaso, Remodulin, and Unituxin in markets across Europe, Asia, the Middle East, Latin America, Canada, and Japan. Manufacturing and development activities are concentrated in the U.S., including facilities and planned capacity in North Carolina, Virginia, Minnesota, and Texas. Geography matters because the business is highly dependent on U.S. reimbursement and regulatory access, while international sales depend on local distributors and approvals. - United States is the core commercial market and operating base - Selected products are sold in Europe, Japan, and other international markets - Tyvaso DPI is marketed in the U.S. while other Tyvaso forms have broader reach - Manufacturing and planned capacity are concentrated in North Carolina, Virginia, Minnesota, and Texas - International sales depend on local distributors and regulatory approvals ## Strategy The company is expanding its commercial franchise in PAH and PH-ILD by growing Tyvaso DPI, Nebulized Tyvaso, and Orenitram while supporting existing products with delivery devices and specialty distribution. It is also investing in manufacturing and organ-manufacturing capacity to support future product launches and potential xeno-organ programs. Longer term, the pipeline targets IPF, PPF, and other rare diseases, which broadens the addressable market beyond pulmonary hypertension. - **Expand Tyvaso franchise** (short-term) — Tyvaso products are central to the company's commercial base and growth profile. - **Increase manufacturing capacity** (medium-term) — Additional facilities are needed to support current demand and future product launches. - **Advance pipeline and organ technologies** (long-term) — New indications and organ manufacturing could diversify revenue beyond PAH. - Grow Tyvaso DPI and Nebulized Tyvaso adoption in PAH and PH-ILD - Expand Orenitram use in pulmonary hypertension treatment - Build manufacturing capacity for current products and future launches - Advance pipeline programs in IPF, PPF, and other rare diseases - Develop organ manufacturing technologies and xeno-organ facilities ## Risks The company is concentrated in treprostinil-based therapies, so any slowdown in Tyvaso, Remodulin, or Orenitram can materially affect revenue. It also faces competition, pricing pressure, reimbursement risk, and patent challenges in a market where large pharmaceutical companies and new entrants can erode share. Operationally, it depends on third-party manufacturers, distributors, and regulators, so supply disruptions or approval delays can affect product availability and launches. - **Concentration in treprostinil-based products** [high] — Tyvaso DPI, Nebulized Tyvaso, Remodulin, and Orenitram make up most revenue. - **Competitive launches in PAH and PH-ILD** [high] — New therapies can take share or force price erosion in the core market. - **Reimbursement and pricing pressure** [high] — Net sales depend on payer coverage, rebates, and government pricing actions. - **Third-party manufacturing and distribution reliance** [medium] — Interruptions can delay supply, reduce sales, or impair launches. - **Patent and generic competition** [high] — Loss of exclusivity or challenges to IP can reduce revenue and margins. - Heavy dependence on treprostinil-based therapies - Competition from new PAH and PH-ILD therapies - Pricing pressure from payers and drug-pricing initiatives - Distributor inventory swings can distort reported sales - Third-party manufacturing and regulatory dependencies - Patent and generic competition risk ## Accounting Revenue is recognized when control of products transfers to distributors, and reported net sales are reduced by gross-to-net deductions such as rebates and chargebacks. Because specialty distributors place monthly or semi-monthly orders and hold inventory reserves, quarterly sales can differ from underlying patient demand. The company also uses estimates for rebates, chargebacks, and other allowances, which can be revised as actual claims data arrives. - **Revenue recognition and gross-to-net deductions** — Affects reported revenue and quarterly comparability - **Distributor inventory and ordering timing** — Creates volatility in reported product sales - **Government program accruals** — Can change revenue and receivable balances - **Stock-based compensation valuation** — Affects operating expenses and equity compensation cost - Revenue recognized at transfer of control to distributors - Gross-to-net deductions reduce reported net product sales - Distributor ordering patterns can create quarter-to-quarter volatility - Rebate and chargeback accruals rely on estimates and later true-ups - Stock-based compensation uses option and RSU valuation assumptions --- *Last updated: 2026-04-29T05:05:26.848349+00:00*